Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Upcoming events
Click here for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) Prescribing Information
Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.1
The most frequently reported adverse reactions are nasopharyngitis (7%), headache (5%) and upper respiratory tract infection (2%).1
In common with other ICS-containing medicines, there is an increased risk of pneumonia. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. Trelegy should be used with caution in patients with unstable or life-threatening cardiovascular disease. Please consult the SmPC for more information1
1. Trelegy Ellipta Summary of Product Characteristics
PM-GB-RS-WCNT-250007 v2.0 | May 2025
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.
PM-GB-NA-WCNT-200004 | July 2024
